Clonidine, an α2-agonist, has been shown to be useful in the treatment of hepatic portal hypertension in cirrhosis. The mechanism has been attributed to a clonidineinduced decrease in sympathetic activity. While clonidine has been shown to stimulate the α2-adrenoceptors of blood vessels, there is limited knowledge of the effects of clonidine on the circular muscle of the hepatic portal vein which regulates its blood flow. To investigate clonidine-induced contraction of the circular muscle of the hepatic portal vein and to clarify the possible role of the endothelium in the contraction, we examined the effects of clonidine on the isometric contraction of endothelium-intact and -removed ring preparations of the rat hepatic portal vein. In endothelium-intact preparations, clonidine caused a concentration-dependent increase in the amplitude of contractions. Inhibition of NO synthesis with N ω -nitro-L-arginine (L-NNA) elevated the resting tone, and increased the amplitude of the clonidine-induced contractions. Inhibition of cyclooxygenase by diclofenac did not change the amplitude of the clonidine-induced contractions observed both in the presence and absence of L-NNA. Application of a single concentration of clonidine induced a clear increase in amplitude of both twitch and tonic contractions. Twitch and tonic contractions induced by clonidine were inhibited by yohimbine. When the endothelium was damaged by sodium deoxycholate, tonic contractions induced by clonidine were completely suppressed, whereas the increase in twitch contractions was not influenced by chemical damage of the endothelium. Neither SKF-96365, a nonselective cation channel blocker, nor superoxide dismutase, a free radical scavenger, in the presence of catalase, changed the tonic contraction induced by clonidine. These results indicate that stimulation of α2-adrenoceptors enhanced twitch contractions and induced tonic contractions in the circular muscle of the rat hepatic portal vein, especially in the absence of NO. The latter, but not the former, occurs through an endothelium-dependent pathway.
Introduction
In cirrhosis, treatment of hepatic portal hypertension is important to prevent varix formation and bleeding in the systemic circulation (Fleig, 1988) . It has been reported that sympathetic nervous activity is increased in cirrhosis (Henriksen et al., 1984) . In in vivo studies, clonidine prevented hepatic portal hypertension in hepatic portal vein-stenosed and cirrhotic rats (Roulot et al., 1989; Lin et al., 1991) and decreased hepatic wedge pressure in cirrhotic patients (Willett et al., 1986; Moreau et al., 1987) . As these effects were associated with a decrease in the plasma noradrenaline concentration without a decrease in the hepatic blood flow, it was considered that clonidine decreased the postsinusoidal hepatic vascular outflow resistance (Willet et al., 1986; Esler et al., 1992) via a decrease in the sympathetic nerve efferent activity (Yomaida et al., 1979) .
In in vitro experiments, clonidine has also been shown to contract longitudinal preparations of the canine hepatic portal vein (Furuta, 1988 ) while clonidine did not contract helical strips of the canine hepatic portal vein (Shoji et al., 1983) . This would indicate that there are differences between the drug responses of the circular and longitudinal smooth muscle layers. Indeed, the relaxation responses to β2-agonists were more sensitive in the circular smooth muscle layer than in the longitudinal smooth muscle layer of the rat hepatic portal vein (Rydningen et al., 1987) . In the rat hepatic portal vein, contractions induced by various neurotransmitters were less sensitive in the circular smooth muscle layer when compared with the longitudinal smooth muscle layer (Mathison, 1983) .
As a decrease in diameter induced prehepatic portal hypertension in the hepatic portal vein, (Szatmari et al., 2002) , it is important to know the responses of the circular muscle to clonidine for an understanding of the actions of this drug in cirrhosis. However, there is little information available concerning the actions of clonidine on the circular smooth muscle layer of the hepatic portal vein.
The endothelial cell layer has been shown to regulate vascular contractility (Furchgott and Zawadski, 1981) and nitric oxide (NO), released from the endothelial cells by various agonists and conditions, plays a major role in the endothelium-dependent relaxation of vascular smooth muscle (Pearson and Vanhoutte, 1993) . Clonidine is known to dilate various arteries and veins via both endothelium-dependent and -independent pathways (Angus et al., 1986; Thorin et al., 1998; Nishina et al., 1999; Lui et al., 2000; Fauaz et al., 2000) . Figueroa et al. (2001) reported that endothelial α2D subtype receptors were coupled to the NO synthetic pathway in the mesenteric artery of the rat. The presence of α2 receptors was also demonstrated on vascular smooth muscle cells (Lepretre et al., 1994; Macrez-Lepretre et al., 1995) .
Histologically, the endothelium is located closer to the circular smooth muscle layer than the longitudinal smooth muscle layer, which would suggest that the smooth muscle cells of the circular layer may be more responsive to endothelial regulation in the rat hepatic portal vein than those of the longitudinal smooth muscle layer. Thus, to clarify the actions of clonidine on the rat portal vein, we performed experiments using ring preparations of the rat hepatic portal vein which were either endothelium-intact or denuded.
Materials and Methods
Male Wistar rats weighing 200-300 g were anesthetized with CO2 and treated in accordance with "the Guiding principles for the care and use of laboratory animals", as approved by the Japanese Pharmacological Society. After sagittal laparotomy and thoracotomy, the inferior vena cava was cut and the animal exsanguinated. The surface of the abdominal organs was cooled with a 4°C modified Tyrode's solution to prevent blood coagulation in the hepatic portal vein. The portal vein was isolated in Tyrode's solution and ring preparations cut under a binocular microscope. To make endothelium-denuded preparations, sodium deoxycholic acid (0.75%) was perfused through the lumen of the vein for 20 sec. The composition of the Tyrode's solution (in mM) was as follows: 137 NaCl, 5.4 KCl, 2.0 CaCl2, 1.0 MgCl2, 0.4 NaH2PO4, 11.9 NaHCO3 and 5.6 glucose (pH 7.3). High K (50 mM) solution was made by replacement of equimolar concentrations of NaCl with KCl and nominally Ca-free solution was made by omitting CaCl2. The ring preparations were mounted horizontally in an organ bath (2.5 ml in volume) at 37°C, and aerated with a mixture of 95% O2 -5% CO2. The force of isometric contractions was measured using a force-displacement transducer (U-gage 10G, Minebea, Karuizawa, Japan) equipped with a strain amplifier (AS2102, NEC, Tokyo, Japan) and recorded on a thermal-pen recorder (Linearcorder WR3310, Graphtec, Tokyo, Japan). The amplitudes of the twitch contractions were measured from the basal tone level to the peak of the spontaneous twitch contractions. The amplitude of the tonic contractions were measured from the basal tone level between the twitch contractions obtained before the application of clonidine. Amplitudes of contractions were measured after the tonic contraction reached a stable level. 
Data analysis
Results are expressed as the mean ± S.E.M. with the number of animals in parenthesis. Statistical significance was assessed by means of the Mann-Whitney test using conventional statistic software (GraphPad Prism, San Diego, USA). P<0.05 was considered to be significant.
Results

Effects of clonidine on endothelium-intact preparations
Ring preparations of the rat hepatic portal vein (endothelium intact) exhibited spontaneous small twitch contractions with an amplitude of 13.4 ± 4.8% (n=24) of 50 mM K-induced contracture, with a frequency of 5.6 ± 0.6 contractions per min (n=18) (which may reflect the activity of the longitudinal smooth muscle layer; Shimamura et al., 2003) . Cumulative application of clonidine (0.001 to 10 µM) induced a concentration-dependent increase in the amplitudes of both the twitch and tonic contractions ( Application of L-NNA (100 µM) increased the amplitude of the twitch contractions and produced a tonic contraction (19.8 ± 4.8%, n=24, and 19.9 ± 0.2%, n=21, of the amplitude of the 50 mM K-induced contracture, respectively). This indicates that nitric oxide is spontaneously The amplitudes of the twitch contractions were expressed as a % of the 50mM K contracture. Number of preparations for each point is 5-6. Asterisks indicate a significant difference from the control (P<0.05).
released in ring preparations of the rat hepatic portal vein. The L-NNA-induced contraction was inhibited by both sodium nitroprusside and nicardipine, a Ca antagonist.
To examine the contribution of nitric oxide to the clonidine-induced contraction, the amplitudes of twitch contractions induced by various concentrations of clonidine were compared with those recorded in the presence of L-NNA. As shown in Fig. 1B , when preparations were pretreated with L-NNA, clonidine still induced contractions.
Diclofenac, a cyclooxygenase inhibitor, did not alter the increase in the amplitude of the twitch contractions induced by clonidine both in the absence and presence of L-NNA (Fig. 1C) .
These results indicate that metabolites of cyclooxygenase did not participate on the clonidineinduced contraction.
To avoid any contribution of the time-and precondition-dependent influences on the clonidine-induced contraction, we applied clonidine in a single dose to preparations instead of as a cumulative application. As shown in Fig. 2 , pretreatment with L-NNA significantly augumented the clonidine-induced tonic contractions at concentrations of 0.01, 0.1 and 1 µM. In nominally Ca-free medium, preparations did not exhibit spontaneous contractions, and neither L-NNA nor clonidine induced any contraction (data not shown). Application of nicardipine also inhibited the generation of spontaneous and clonidine-induced tonic contractions (data not shown).
Basal tension recorded in the presence of spontaneously released NO (basal NO), recorded before application of L-NNA, was restored by administration of SNP in the presence of L-NNA.
To assess the possible contribution of NO in clonidine-induced contractions, we examined the effects of clonidine on the tonic contractions obtained in both the L-NNA-treated and untreated preparations in the presence of diclofenac. After an L-NNA-induced tonic contraction was achieved, the contraction was suppressed back to the basal tension level by application of SNP and clonidine was then applied cumulatively. As shown in Fig.3B , the amplitude of the clonidine-induced contractions in both L-NNA-treated and untreated preparations did not differ, indicating that there was no involvement of NO in the clonidine-induced contraction. Yohimbine, an α2 antagonist, inhibited the amplitude of the clonidine-induced twitch and tonic contractions to the control level both in the absence and presence of L-NNA ( Figs. 2A and  3A) . Thus, both the augmentation of twitch contractions and the generation of a tonic contraction by clonidine occur via α2-adrenoceptor stimulation.
Clonidine-induced tonic contraction in endothelium-intact and -removed preparations
To study the contribution of the endothelium, the effects of clonidine were compared in endothelium-intact and -removed preparations. In endothelium-intact preparations, 1 µM clonidine produced tonic contractions with an amplitude of 17.3 ± 2.7% (n=11) of the 50 mM Kinduced contracture. On the other hand, in endothelium-removed preparations, the amplitudes of the tonic contractions induced by application of the same concentration of clonidine were reduced to 2.5 ± 1.2% (n=7) of the 50 mM K-induced contracture (Fig. 4) . In the presence of diclofenac, L-NNA and 1 µM clonidine both produced marked tonic contractions in endotheliumintact preparations (14.5 ± 2.5% (n=11) and 22.9 ± 5.0% (n=11) of the 50 mM K-induced contractions, respectively), whereas neither L-NNA nor clonidine produced tonic contractions in endothelium-removed preparations (Fig. 5) . Augmentation of the twitch contractions induced by clonidine was not suppressed by endothelium-removal, in the presence of diclofenac and L-NNA. The amplitude of 1 µM clonidine-induced twitch contractions in endothelium-intact andremoved preparation was 80 ± 15% (n=6) and 81 ± 15% (n=6) of the 50 mM K-induced contracture, respectively. Thus, augmentation of twitch contractions and induction of tonic contractions by clonidine occurred by way of different mechanisms; the former contractions are endothelium-independent while the latter are endothelium-dependent.
In the presence of L-NNA, SKF-96365 (a nonselective cation channel inhibitor) did not inhibit clonidine-induced tonic contractions (Fig. 6B) . Pretreatment of the preparations with 150 U/ml SOD in the presence of 1200 U/ml catalase did not change the 1 µM clonidine-induced tonic contractions (Fig. 6C) .
Discussion
Since the first finding of endothelium-dependent relaxation, many agonists, including NO, have been shown to release endothelium-derived relaxing factor (EDRFs) which inhibits vascular smooth muscle contraction (Furchgott and Zawadski, 1981; Pearson and Vanhoutte, 1993) . In both longitudinal and circular muscle preparations of the hepatic portal vein, NO was shown to inhibit contraction, suggesting that contractility of the hepatic portal vein was regulated by NO (Feletou et al., 1989; Shimamura et al., 2000) . However, acetylcholine-induced EDRF released from either aorta or femoral artery failed to change the spontaneous contraction of the rat portal vein longitudinal muscle preparation (Vedernikov et al., 1987; Feletou et al., 1989) . Thus, the possible contributions of both EDRF and other factors released from the endothelium on the smooth muscle of the hepatic portal vein were still obscure. and -removed (filled column) hepatic portal vein. The amplitudes of tonic contraction were measured from the broken line in A after the clonidine-induced contractions became stable, and are expressed as a % of the 50 mM K contracture. Number of observations is 6 for E(+), and 8 for E(-). Asterisks indicate a significant difference from E(+) (P<0.05).
Basal release of NO has been demonstrated in both the rat aorta (Martin et al., 1986) and the rabbit saphenous vein (McGrath et al., 1990) . In the present experiments, we observed that L-NNA elevated the basal tone of ring preparations of the rat hepatic portal vein (Figs. 1 and 2) , and confirmed that NO was spontaneously released in these preparations (Shimamura et al., 2000) .
The present study has shown that clonidine enhanced the amplitude of twitch contractions and generated tonic contractions in ring preparation of the rat hepatic portal vein. Although the twitch contractions induced by clonidine were augmented by L-NNA, removal of the endothelium did not suppress the augmentation (Figs. 4 and 5) . As augmentation of the twitch contractions induced by clonidine was inhibited by yohimbine, the augmenting action of clonidine involves α2 receptor stimulation of vascular smooth muscle cells. The presence of α2 receptors on smooth muscle cells of vascular muscle has been reported (Fauaz et al., 2000) .
Augmentation of L-type Ca channel currents by clonidine was also reported in isolated smooth muscle cells of the rat hepatic portal vein (Lepretre et al., 1994; Macrez-Lepretre et al., 1995) . In the present experiments, we did not examine the possible contribution of α2 receptors at prejunctional nerve terminals, however, it is unlikely that clonidine-induced augmentation of twitch contractions occurred via prejunctional α2 receptor stimulation, as prejunctional α2 receptors are involved with the autoinhibition of norepinephrine release (Bobalova and Mutafova-Yambolieva, 2001 ). The involvement of α2 agonist-induced NO release in the contraction was not marked, as the spontaneously released NO could be restored by SNP (Fig. 3) . Thus our observation may support previous studies (Feletou et al., 1989; Vedernikov et al., 1987) which showed negative evidence for acetylcholine-mediated EDRF in the rat portal vein. Tonic contractions induced by clonidine were endothelium-dependent (Fig. 4) , and L-NNA enhanced the amplitude of these tonic contractions. Thus, clonidine stimulates the release of a contractile factor or inhibits the release of a relaxing factor from the endothelium of the rat hepatic portal vein. When NO synthesis was blocked by L-NNA, the tonic contractions induced by clonidine were markedly enhanced (Fig. 2) . Therefore, inhibition of NO synthesis may not be involved in the clonidineinduced contractions, at least not in the presence of L-NNA.
Several possible candidates for the contractile factor involved in clonidine-induced tonic contractions were examined, such as superoxide, prostanoids and endothelin. Although superoxide has been shown to contribute to endothelium-dependent contraction (Katusic and Vanhoutte, 1989; Yang et al., 2002) , the combination of SOD with catalase did not inhibit clonidine-induced tonic contractions. Such a combination of enzymes was reported to rapidly metabolize superoxide (Yang et al., 2003) , and our results showed that the contribution of superoxide to the clonidine-induced tonic contractions may be negligible. Diclofenac, a cyclooxygenase inhibitor, failed to change the amplitude of the tonic contractions induced by clonidine in the presence and absence of L-NNA. As diclofenac did not produce any change on the contractility of the rat portal vein in the present experiments, cyclooxygenase metabolites did not contribute to the clonidine-induced responses in the rat hepatic portal vein. A possible contribution of nonselective cation channel activation via endothelial α2 receptor stimulation was also excluded, as SKF-96365, a nonselective cation channel inhibitor, did not suppress clonidineinduced tonic contractions. Thus, the detailed mechanism involved in the endotheliumdependent contraction caused by clonidine remains to be elucidated.
In conclusion, our results indicate that clonidine induces endothelium-dependent tonic contractions in rat hepatic portal vein ring preparations. In clinical use, the plasma concentration of clonidine is approximately 1 ng/ml in systemic veins (Wing et al., 1977) . In the present study we used clonidine at a 100 times higher concentration, which may be achieved in hepatic portal venous plasma after oral administration. In the absence of NO, clonidine may induce prehepatic portal hypertension by a tonic contraction of the circular smooth muscle of the hepatic portal vein and this untoward effect needs to be considered in the treatment of portal hypertension by oral administration of clonidine.
